Novo Nordisk was granted a label expansion soon afterward for dose of 2.0 mg for persons with T2D whose hyperglycemia remained uncontrolled by other agents.1References:1. Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. Novo Nordisk. Fick M, Skydsgaard N. Novo weight-loss drug Wegovy shows heart benefit in trial. Tirrell M. Wegovy shown to reduce risk of heart attack, stroke in major cardiovascular trial.

Source: CNN August 08, 2023 20:57 UTC